Target Research Articles
-
Can CoRegen's Treg Platform Dismantle Solid Tumors' Immune Shield?
10/22/2026
Backed by $93 million, CoRegen is bringing a novel Treg-engineering strategy into the clinic to test whether CRG-150 can dismantle solid tumors’ immune defenses.
-
Discovery & Development US 2026 - Key Notes From San Diego
10/19/2026
Key takeaways from D&D US 2026 on Pfizer’s complex oncology targets, AI-enabled discovery, and the shift toward human-based NAMs.
-
Inside Discovery On Target 2026: New Modalities, AI, And A Higher Funding Bar
10/7/2026
Discovery on Target 2026 showed how new modalities and AI are expanding drug discovery as investors demand stronger data and clearer paths to value.
-
Targeting p27 To 'Let Biology Do The Work' With Stacy Blain, CEO, Concarlo Therapeutics
9/29/2026
Stacy Blain, PhD, turned 30 years of p27 research into Concarlo’s LOCKTAC, a molecular glue designed to restore natural CDK2/4/6 inhibition in cancer.
-
Viewing Treatment Resistance As A Target
9/16/2026
Viewing treatment resistance as a target instead of an undesirable side effect could allow effective treatments to work for longer.
-
Target Transcription Factor States, Not Pockets
8/21/2026
Transcription factors expose broad protein–DNA and protein–protein interfaces, contain intrinsically disordered regions, and exchange partners as cellular context changes.
-
Beyond Apoptosis: Context Is The Target
8/17/2026
Cells that evade apoptosis do not necessarily evade death; they may remain vulnerable to ferroptosis, pyroptosis, necroptosis, or another regulated cell death program.
-
Alpha-Synuclein Is Not One Target
8/14/2026
Alpha-synuclein is not one target, and a nanobody is not a smaller antibody with automatic access.
-
Drug Discovery AI Has A Ground Truth Problem
7/27/2026
If the goal is more healthy years of life, the bottlenecks are target identification, target validation, and clinical testing. Why is AI not transforming those steps? Because the data are not there.
-
Wondering If Your Org Should Purchase R&D Datasets?
7/1/2026
Pharma/biotech companies are increasingly looking to access large-scale data sets to fill gaps in their computational biology capabilities. Be prepared for the investment.